Global chemical hazard labeling system would confuse consumers if applied to pharmaceuticals -- PhRMA.
GLOBALIZED CHEMICAL HAZARD LABELING WOULD BE "SOURCE OF CONFUSION," PhRMA VP-Manufacturing & Quality Control Thomas White maintained at a State Department meeting on international harmonization of chemical safety and health information June 5 in Washington, D.C. Patients and other users "would be needlessly alarmed and confused by labeling that is inappropriate and has no relevance to the safe and effective use of pharmaceuticals for their intended therapeutic indications," the Pharmaceutical Research & Manufacturers of America maintained in response to a Federal Register notice on the harmonization initiative.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth